Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 2,738 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,738 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $35.26, for a total value of $96,541.88. Following the sale, the chief financial officer owned 140,031 shares of the company’s stock, valued at approximately $4,937,493.06. This represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total value of $173,454.48.

Twist Bioscience Stock Up 5.7%

TWST stock opened at $40.22 on Wednesday. The firm has a 50-day moving average price of $31.82 and a 200-day moving average price of $31.14. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $55.33. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.46 billion, a P/E ratio of -30.70 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The company had revenue of $99.01 million for the quarter, compared to analyst estimates of $97.40 million. As a group, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analysts Set New Price Targets

TWST has been the topic of several recent research reports. Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Stephens started coverage on Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Evercore ISI reiterated an “outperform” rating and issued a $42.00 price objective on shares of Twist Bioscience in a report on Monday, January 5th. Finally, Barclays boosted their target price on shares of Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $28,000. Smartleaf Asset Management LLC lifted its holdings in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares during the period. National Bank of Canada FI bought a new stake in Twist Bioscience during the third quarter valued at $46,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Twist Bioscience by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after acquiring an additional 302 shares during the period. Finally, Geneos Wealth Management Inc. bought a new position in shares of Twist Bioscience in the 2nd quarter worth about $97,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.